However, in the middle to late stages of cancer, tumor cells may develop resistance to TGF-β or be reprogrammed by it (75), transforming TGF-β into a tumor promoter that induces epithelial–mesenchymal transition (EMT) and enhances the invasive and metastatic capabilities of tumor cells, as well as their resistance to chemotherapy. This evidence concerns the gene TGFB1 and cancer.